Back to Archived News
Ryogen Is Awarded Two Additional Patents for Human Genes
Tuesday, October 19, 2010
Suffern, NY – October 19, 2010 – Ryogen LLC, a genomic research and development company focusing on genes with applications in biomedical research, has been awarded two additional patents on human genes.
U.S. Patent No. 7,754,424, titled “Isolated genomic polynucleotide fragments from chromosome 12 that encode human carboxypeptidase M and the human mouse double minute 2 homolog”, claims isolated genomic polynucleotide fragments that encode human mouse double minute 2 homolog as well as fragments of contiguous exon-intron and intron-exon regions, transcription factor binding regions and other noncoding regions such as 5’ and 3’ noncoding regions and intron regions, complementary polynucleotides, microarrays, vectors and host cells containing these fragments. The patent also claims methods for detecting the claimed polynucleotide fragments and methods for obtaining human mouse double minute 2 homolog. The protein encoded by the claimed sequences is thought to play a role in modulating production of p53 levels in an individual as well as specifically a role in treatment of sarcoma and leukemia.
U.S. Patent No. 7,786,280, titled “Isolated genomic polynucleotide fragments from chromosome 10q25.3 that encode human soluble aminopeptidase P,” claims isolated genomic polynucleotide fragments that encode soluble human Aminopeptidase P, complementary polynucleotides, vectors and host cells containing these fragments and a method for obtaining soluble Aminopeptidase P. The protein encoded by the claimed sequences is thought to play a role in modulating bradykinin and substance P levels in an individual as well as specifically a role in acquired or inherited angioedema or acute pancreatitis.
“I am very pleased with the USPTO’s decision to award us these patents, bringing number of our issued patents to seven” said Dr. James W. Ryan, the named inventor on the patents and Chief Scientist at Ryogen.
“These patents are important additions to the Ryogen’s existing patent portfolio,” said Valeria Poltorak, Ryogen’s Executive Vice President. “We plan to continue licensing our intellectual property to make it accessible to the research community” she concluded.
About Ryogen LLC
Ryogen LLC, located in Suffern, N.Y., owns an intellectual property (IP) portfolio of seven gene patents and 15 patent applications directed to various genes with potentially important applications in biomedical research and, ultimately, diagnostics and drug development. Ryogen was formed with the purpose of making its intellectual property accessible to researchers via licensing of its patents. Ryogen is a business unit in the IP Incubator operated by IP Holdings LLC, and Ryogen is managed by General Patent Corporation (GPC). For further information, visit www.ryogen.com.
About IP Holdings LLC
IP Holdings LLC, based in Suffern, N.Y., is an IP-centric merchant banking organization that provides IP‑related financial services and operates an idea incubator that focuses on patent commercialization. IP Holdings is a member of the GPC Group of Companies. For additional information, visit www.ip-holdings.com.
About General Patent Corporation
General Patent Corporation, headquartered in Suffern, N.Y., is a leading intellectual property (IP) boutique focusing on patent licensing and patent enforcement as well as IP valuation, IP strategy, IP management and other IP advisory services. For more information, visit www.generalpatent.com.
Back to Archived News